PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels

Labelling - New safety information - Supply - COVID

Date

2022-01-17

Country

Canada

Product

PAXLOVID (150 mg nirmatrelvir; 100 mg ritonavir)

Category

Drugs & medical

Source

Health Canada

Copied automatically from the Government of Canada. Details may be shortened or out of date; the official notice is the authoritative source. Disclaimer

What to do

1. Check the product name, strength and lot number against the official notice.
2. Do not stop a prescribed medicine without talking to your doctor or pharmacist first.
3. Ask the pharmacy or supplier about a replacement or refund.

General guidance from Recall Atlas. The official notice from the Government of Canada has the exact models, batch codes and remedy, and it takes priority.

Other drugs & medical recalls in Canada

1. 2022-01-17
2. CA
   Drugs & medicalType II

   Crag Lateral Flow Assay

   Lack of efficacy

   Health CanadaOfficial notice →
3. CA
   Drugs & medicalType II

   Batec Mobility Products

   Manufacturing defect

   Health CanadaOfficial notice →
4. CA
   Drugs & medicalType II

   Endurant Iis Stent Graft System

   Manufacturing defect

   Health CanadaOfficial notice →
5. 2022-01-12
6. CA
   Drugs & medical

   Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer

   Product safety

   Health CanadaOfficial notice →
7. 2022-01-11
8. CA
   Drugs & medical

   Shelf Life Extension for the SPIKEVAX (elasomeran) COVID-19 Vaccine with Printed Expiry Dates on Vial and Carton Labels

   Labelling - Packaging - Product safety - Supply

   Health CanadaOfficial notice →
9. 2022-01-10
10. CA
    Drugs & medicalType II

    Simplexa Covid-19 Direct Assay

    Manufacturing defect

    Health CanadaOfficial notice →